Affimed NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AFMD Nasdaq 8731 https://www.affimed.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Affimed NV

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13 - Jan 9th, 2023 11:30 am
Investors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last year - Dec 28th, 2022 11:41 am
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia - Dec 22nd, 2022 11:30 am
Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks - Dec 16th, 2022 2:35 pm
Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside - Dec 12th, 2022 6:01 pm
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting - Dec 12th, 2022 3:00 pm
Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo - Dec 12th, 2022 10:50 am
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma - Dec 10th, 2022 8:00 pm
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting - Dec 10th, 2022 7:20 pm
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting - Dec 1st, 2022 9:05 pm
Why Shares of Affimed Fell Thursday - Nov 17th, 2022 9:01 pm
Affimed Third Quarter 2022 Earnings: Beats Expectations - Nov 17th, 2022 10:17 am
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates - Nov 15th, 2022 12:45 pm
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress - Nov 15th, 2022 11:30 am
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting - Nov 7th, 2022 1:05 pm
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022 - Nov 4th, 2022 10:30 am
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101 - Nov 3rd, 2022 1:15 pm
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting - Nov 3rd, 2022 1:05 pm
Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for - Nov 2nd, 2022 2:01 pm
Affimed to Present at the 2022 Jefferies London Healthcare Conference - Nov 1st, 2022 10:30 am